Kiran Mazumdar Shaw is known as India’s wealthiest self-made women entrepreneur who found a biopharmaceutical firm in 1978.
Kiran Mazumdar Shaw is a first-generation Indian Women Entrepreneur and the chairperson & managing director of Biocon India Limited, a biotechnology company based in Bangalore, India. She founded Biocon India Ltd in 1978.
Personal Life and Education
She was born on 23 March 1953 in Pune, Maharashtra state, to Gujarati parents. Her father, Rasendra Mazumdar, was the head brewmaster at United Breweries.
- Bishop Cotton Girl’s High School Bangalore.
- Mount Carmel College, Bangalore Pre-University Courses
- Sc. (Zoology Hons.), Bangalore University (1973)
- Post-Graduate Diploma, Malting and Brewing, Ballarat Institute of Advanced Education, Melbourne, Australia (1975)
- Honorary Doctorates from several prestigious universities, including:
- Deakin University, Victoria, Australia
- Heriot-Watt University, Edinburgh, UK
- University of Glasgow, Scotland,
- UK University of Abertay, Dundee, Scotland, UK
- Ballarat University, Australia
- Presidency University, Kolkata, India
- First-generation entrepreneur
- Founded Biocon in 1978
- Non-Executive Chairperson, Syngene International
- Board member, Infosys
- Board member, Narayana Hrudayalaya
- Board member, United Breweries
- Vice Chair, US India Business Council (USIBC)
- Member, National Academy of Engineering (NAE), U.S.
- Full-term member, MIT Corporation, U.S.
- Member, Board of Directors, U.S.-India Business Council
- Member, Advisory Council, UK-India Business Council
- Member, Board of Trustees, Keck Graduate Institute, U.S.
- Global Alumni Ambassador, Australia
- Signatory, The Giving Pledge
- 45 years of experience in Biotechnology
Achievement and Award
- Recipient of Padma Shri (1989), Padma Bhushan (2005)
- Recipient of EY World Entrepreneur of the Year (2020) and EY Entrepreneur of the Year India Award (2019)
- Recipient of Order of Australia (2020)
- Recipient of ICMR’s Lifetime Achievement Award for Outstanding Achievement in Healthcare (2019)
- Recipient of AWSM Award for Excellence (2017)
- Knight of the National Order of the French Legion of Honour (2016)
- Recipient of Othmer Gold Medal (2014)
- Recipient of Global Economy Prize for Business (2014)
- Financial Times’ top 50 women in business list (2019)
- 68th most powerful woman in the world by Forbes (2019)
- EY World Entrepreneur Of The Year (2020)
- Bharat Asmita National Award (2021)
About Biocon Biopharmaceutical Limited
Biocon Limited is an Indian biopharmaceutical company based in Bangalore, India. The Company manufactures generic active pharmaceutical ingredients that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. As per Forbes, it is the first company to get approval from the USFDA.
Biocon has evolved since its inception in 1978 from an industrial enzymes company to a fully-integrated, innovation-led, emerging global biopharmaceutical enterprise committed to reducing therapy costs of chronic conditions like diabetes, cancer and autoimmune diseases.
Started in 1978 with just Rs 10,000 in hand Biocon today has become India’s largest biotechnology company. They focus on delivering affordable innovation and reducing costs of therapy diseases.
The company’s initial projects were the extraction of papain (an enzyme from papaya used to tenderize meat) and isinglass (obtained from tropical catfish and used to clarify beer). Within a year of its inception, Biocon India was able to manufacture enzymes and export them to the U.S. and Europe, the first Indian company to do so.
Mazumdar spearheaded Biocon’s evolution from an industrial enzymes manufacturing company to a fully integrated bio-pharmaceutical company with a well-balanced business portfolio of products and a research focus on diabetes, oncology and auto-immune diseases.
She also established two subsidiaries: Syngene (1994) which provides early research and development support services on a contract basis and Clinigene (2000) which focuses on clinical research trials and the development of both generic and new medicines. Clinigene was later merged with Syngene.
In 2004, Mazumdar-Shaw started a corporate social responsibility wing at Biocon, the Biocon Foundation. The Foundation focuses on health, education and infrastructure, especially in rural areas of Karnataka which lack healthcare facilities
Revenue – ₹4,079 crores (US$570 million) (2016–17)
Founding Year: 1978
Investors: Fusion Microfinance, Glympse Bio